Register a trial

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03314298




Registration number
NCT03314298
Ethics application status
Date submitted
6/08/2017
Date registered
19/10/2017

Titles & IDs
Public title
A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole
Scientific title
A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole From Subcutaneous Testosterone and Anastrozole (T+Ai) in Premenopausal Women
Secondary ID [1] 0 0
HAV-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Mammographic Density 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - testosterone anastrozole

Experimental: testosterone anastrozole implant - testosterone 80mg Anastrozole 4 mg single as a subcutaneous pellet


Treatment: Drugs: testosterone anastrozole
subcutaneous testosterone and anastrozole
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
testosterone Cmax
Timepoint [1] 0 0
Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
Primary outcome [2] 0 0
testosterone AUC
Timepoint [2] 0 0
Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
Primary outcome [3] 0 0
testosterone T1/2
Timepoint [3] 0 0
Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
Primary outcome [4] 0 0
anastrozole Cmax
Timepoint [4] 0 0
Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
Primary outcome [5] 0 0
anastrozole AUC
Timepoint [5] 0 0
Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
Primary outcome [6] 0 0
anastrozole T1/2
Timepoint [6] 0 0
Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
Secondary outcome [1] 0 0
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Timepoint [1] 0 0
The outcome measures will be reported weekly until study completion-3 months
Secondary outcome [2] 0 0
dihydrotestosterone metabolism
Timepoint [2] 0 0
3 months
Secondary outcome [3] 0 0
breast elasticity
Timepoint [3] 0 0
Breast tissue elasticity will be measured by shear wave ultrasound at baseline and on Days 29, 57 and 85

Eligibility
Key inclusion criteria
1. Agree to and be capable of understanding and signing an Informed Consent Form.
2. Patients seeking treatment with Investigational Product for the reduction in high mammographic breast density (MBD).
3. Pre-menopausal levels of Follicular stimulating hormone/Leutinizing hormone/estradiol(follicle stimulating hormone/luteinizing hormone/oestrogen) according to the definition of "pre-menopausal range" for the laboratory involved.
4. Volpara Density volumetric breast density of =15.5% (combined average both breasts)
5. Age between 35-55 years inclusive.
6. Body weight between 50-90 kg inclusive.
7. BMI between 20-30 kg/m2 inclusive.
8. Good venous access for venepuncture.
9. In good general health without clinically significant cardiac, respiratory, or psychiatric disease.
10. Negative pregnancy test in women of childbearing potential (premenopausal or less than 12 months of amenorrhea post-menopause, and who have not undergone surgical sterilisation), no more than seven days before the first dose of Investigational Product.
11. For women of childbearing potential who are sexually active, agreement to use a highly effective, non-hormonal form of contraception (Mirena (TM) allowed) during and for at least six months after completion of treatment with Investigational Product; OR, a fertile male partner willing and able to use effective non-hormonal means of contraception (barrier method of contraception in conjunction with spermicidal jelly, or surgical sterilisation) during and for at least six months after completed dosing Investigational Product.
Minimum age
35 Years
Maximum age
55 Years
Sex
Females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Presence of breast cancer.
2. Previous or concomitant other malignancy (non-breast, other than skin) within the previous five years.
3. Diabetes mellitus or glucose intolerance defined as a fasting glucose of = 6 mmol/L.
4. History of coronary artery disease.
5. Risk of transmitting Human Immunodeficiency Virus or viral hepatitis via infected blood.
6. Existing testosterone, oestrogen and/or anastrozole treatment.
7. Concomitant medication which induces or inhibits CYP3A4 (Listed in Appendix A).
8. Current warfarin usage.
9. Prolonged systemic corticosteroid treatment, inhalation and topical steroids allowed.
10. Known hypersensitivity to any component of Investigational Product.
11. Systemic reproductive hormone replacement therapy.
12. Systemic hormonal contraception.
13. Participation in another clinical trial of an Investigational Product within 30 days of entry into the present trial or within 4-5 half-lives of the Investigational Product, whichever is the longer.
14. Use of any product containing ginseng within 30 days of screening.
15. Pregnant or lactating women.
16. Unable to comply with trial requirements.

Study design
Purpose of the study
Prevention
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/08/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
17/04/2018
Sample size
Target
Accrual to date
Final
11
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
Wellend Health - Toorak Gardens
Recruitment postcode(s) [1] 0 0
5065 - Toorak Gardens

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Havah Therapeutics Pty Ltd
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Stephen N Birrell, Md PhD
Address 0 0
Wellend Health
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT03314298